Explore the Category

Ashburton Global 1200 Equity ETF hits R1bn under management

06 January 2021 | Equities

The Ashburton Global 1200 Equity Fund of Funds ETF (ASHEQF) has reached the notable R1bn assets under management milestone in just over three years since it launched.

Has 2020 shifted your financial goals?

06 January 2021 | General

Economies at a glance report - December 2020

06 January 2021 | Economy

Has 2020 shifted your financial goals?

06 January 2021 | General

quick poll

Question

Do you think short-term insurance broking will survive the AI plus humanoid robotics age?

Answer

Human first always Not a chance Possibly maybe Yes, but reimagined

View the Results

Could recovery be curbed until 2022?

03 January 2021 | General

Investing with style – A guide to understanding investment styles and strategies

11 December 2020 | General

In investing, good things come to those who wait

10 December 2020 | General

Short-Term Uncertainties as COVID-19 Cases Spike

09 December 2020 | Economy

Strong rebound, but growth momentum expected to slow

09 December 2020 | General

2020: Lessons for the long-term investor

08 December 2020 | General

2021 Economic Outlook: Anticipated vaccine rollout lights up an uneven post-pandemic path

08 December 2020 | General

Financial market outlook for 2021: Virus or vaccine victorious?

08 December 2020 | General

« ‹ 218 219 220

221

222 223 224 › »

Investments

Ashburton Global 1200 Equity ETF hits R1bn under management

Has 2020 shifted your financial goals?

Economies at a glance report - December 2020

Has 2020 shifted your financial goals?

Could recovery be curbed until 2022?

Investing with style – A guide to understanding investment styles and strategies

In investing, good things come to those who wait

Short-Term Uncertainties as COVID-19 Cases Spike

Strong rebound, but growth momentum expected to slow

2020: Lessons for the long-term investor

2021 Economic Outlook: Anticipated vaccine rollout lights up an uneven post-pandemic path

Financial market outlook for 2021: Virus or vaccine victorious?